Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019.
Extracorporeal membrane oxygenation
Pharmacokinetics analysis
Remdesivir
Severe COVID-19
Journal
IDCases
ISSN: 2214-2509
Titre abrégé: IDCases
Pays: Netherlands
ID NLM: 101634540
Informations de publication
Date de publication:
2021
2021
Historique:
received:
08
11
2021
revised:
14
11
2021
accepted:
16
11
2021
pubmed:
23
11
2021
medline:
23
11
2021
entrez:
22
11
2021
Statut:
ppublish
Résumé
Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis of remdesivir in patients with severe COVID-19 requiring extracorporeal membrane oxygenation (ECMO). A 63-year-old American man who underwent mechanical ventilation and ECMO for severe COVID-19 was administered remdesivir for ten days. The loading dosage was 200 mg at 7 PM on day 12 and 100 mg daily at 0:00 PM from day 13-21, administered within 1 h. The pharmacokinetic analysis was performed. The serum creatinine concentration was within the normal range of 0.5-0.7 mg/dL during treatment. According to the pharmacokinetic analysis, the plasma concentrations of remdesivir and GS-441524 4 h after administration (C
Identifiants
pubmed: 34804800
doi: 10.1016/j.idcr.2021.e01343
pii: S2214-2509(21)00299-7
pmc: PMC8596653
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e01343Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors report no conflict of interest.